Bristol Myers Squibb Partners With Pathos AI, Tempus on AI-Driven Alzheimer's Drug Development

Bitget2026/10/23 13:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol Myers Squibb entered multi-year collaborations with Pathos AI and Tempus AI to advance AI-driven drug development for neurological diseases.
The drugmaker leads Pathos's Series E financing, gaining access to its Pathos Foundry AI platform across its broader R&D portfolio.
Three-year exclusive neuroscience rights aim to improve clinical-trial design for Alzheimer's disease and other neurological conditions.
Tempus will build a de-identified, longitudinal dataset covering hundreds of thousands of patients with neurological conditions.
Pathos will license the dataset under a five-year, $55 million agreement to support disease research and more targeted clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023830134) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol Myers Squibb Partners With Pathos AI, Tempus on AI-Driven Alzheimer's Drug Development

You may also like

Crypto prices